Mylan Escapes Novartis MS Drug Patent Suit

By Adam Lidgett · June 17, 2019, 7:11 PM EDT

Mylan Pharmaceuticals Inc. was able to evade a patent suit from Novartis seeking to block generic versions of its multiple sclerosis drug Gilenya when a judge said Monday that Delaware federal...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order - -Memorandum and Order

Case Information

Case Title

Novartis Pharmaceuticals Corporation v. Accord Healthcare Inc. et al

Case Number

Court

Delaware

Nature of Suit

Patent - Abbreviated New Drug Application(ANDA)

Date Filed

July 16, 2018

Recent Articles By Adam

June 03, 2025
Patent Deals Accelerate Access To Generics, Drug Group Says
April 11, 2025
Foreign Cos. Say Anti-Choking Device Patent Is Invalid
April 11, 2025
Aurinia Sues Lotus Alleging Lupus Drug Patent Infringement
April 08, 2025
Pacira Reaches IP Deal Allowing Generic Painkiller In 2030
April 07, 2025
Incyte Can't Get Pretrial Win In Novartis Royalty Fight
April 03, 2025
Texas Appeals Court Backs UT Royalty Award In Pet Co. Suit
March 27, 2025
Fitch Even Sues Ex-IP Client In Effort To End Malpractice Case
March 24, 2025
Amgen Wants $50M Leukemia Drug Patent Verdict Thrown Out
March 18, 2025
Bausch Eye Vitamin Case Should Go To Jury, Judge Says
March 18, 2025
AI Healthcare Co. Accuses Test-Maker Of Infringing Patents